Seena Magowitz Pancreatic Cancer Foundation The Face and Voice of Pancreatic Cancer
Pancreatic Cancer Research Foundation Pancreatic Cancer Research Fund Roger Magowitz Dr. Daniel Von Hoff Jai Pausch, Spokesperson Howard Young, Survivor
Pancreatic Cancer Charity

Seena Charity Plaza

Donations

$500 Challenge

Find Us On Facebook

Cutting Off Fuel Supply



Bookmark and Share

New Approach of Fighting Pancreatic Cancer: 9/2010

Overview:

As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer. More than 90 percent of patients die within the first year of diagnosis. Recent advancements have had little impact, and a new approach is desperately needed.

Scientists have suggested the possibility of "starving" cancer cells to death by depriving them of a specific nutrient that they require for survival. Recent studies have demonstrated that most cells acquire mutations causing them to become addicted to a continual supply of nutrients to produce the energy needed for survival and proliferation. In most cancers, this nutrient is glucose.

Using modern tumor imaging, it is possible to monitor a tumor's glucose utilization and such tests are now routinely used in clinical practice. In most cases, the more glucose a tumor is using, the more advanced the tumor and the greater likelihood of spread. Similarly, if a tumor is using less glucose as a response to chemotherapy, then it is a good indication that the tumor is responding to treatment.

Pancreatic cancer presents a unique challenge because it is addicted to another molecule, glutamine, rather than glucose. Glutamine is an amino acid that helps build muscle mass and is used by some cells for energy. When cancer feeds or metabolizes excess amounts of gluatamine, it can lead to extreme weight loss by robbing other cells of this important nutrient, a condition from which many pancreatic cancer patients suffer. In addition, the waste that is a by-product of this process generates an intense reaction from surrounding normal cells, which then secrete growth factors that help tumor cells grow. Cancers that use excess glutamine are often resistant to standard forms of chemotherapy, another characteristic of pancreatic cancer.

Specific Research Goals:

Project Status:

This SU2C Dream Team is conducting clinical trials to test new ways of cutting off the fuel supply to pancreatic cancer. One set of trials uses a drug to break through the tough coating surrounding the cancer so that a second drug can kill the cancer cells. This drug combination is showing positive preliminary results in actually shrinking tumors. Another effort is aimed at examining a tumor's metabolism to personalize treatment for individual patients so that the effectiveness of treatment is maximized and side effects are minimized. The team is also developing new ways to get images of pancreatic cancer, so that the tumor's response to treatment can be observed. This will make personalized treatment a reality for pancreatic cancer patients.

Leaders:
Craig B. Thompson, M.D.,
president and CEO, Memorial Sloan-Kettering Cancer Center
Daniel D. Von Hoff, M.D., senior investigator and physician-in-chief, Translational Genomics Research Institute (TGen)

Principals:
Chi V. Dang, M.D., Ph.D., vice dean for research, Johns Hopkins University School of Medicine
Joshua D. Rabinowitz, M.D., Ph.D., assistant professor of chemistry and integrative genomics, Princeton University
Geoffrey M. Wahl, Ph.D., Professor, Gene Expression Laboratory, the Salk Institute for Biological Studies

Advocates:
Julie Fleshman
Barton A. Kamen
Howard Young
Randall Katz


Seena Magowitz Pancreatic Cancer Foundation does not intend to provide specific medical advice. It only provides general information to help users better understand their health. SMF urges all users to always consult with qualified physicians for any diagnosis or answers to specific questions.


This page was last modified on 13 February 2012 at 16:51
Howard Young's globalCure Atlanta Golf Classic